Burkholderia Infections - Pipeline Review, H2 2016 - Overview, Comparative Analysis & Pipeline Products Glance - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Burkholderia Infections - Pipeline Review, H2 2016" report to their offering.

Burkholderia infections are caused by Burkholderia cepacia bacteria. Symptoms include low-grade fever, progressing to much more serious conditions, including pneumonia, cough, congestion, shortness of breath, and wheezing. Predisposing factors include weakened immune system and lung diseases. Treatment includes antibiotics.

This report provides comprehensive information on the therapeutic development for Burkholderia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkholderia Infections and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • Aridis Pharmaceuticals LLC
  • Arno Therapeutics Inc
  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc
  • Eumedica SA
  • Grifols SA
  • Sarepta Therapeutics Inc
  • Soligenix Inc
  • Syntiron LLC
  • TGV-Laboratories
  • Vault Pharma Inc

Key Topics Covered:

  1. Introduction
  2. Burkholderia Infections Overview
  3. Therapeutics Development
  4. Pipeline Products for Burkholderia Infections - Overview
  5. Pipeline Products for Burkholderia Infections - Comparative Analysis
  6. Burkholderia Infections - Therapeutics under Development by Companies
  7. Burkholderia Infections - Therapeutics under Investigation by Universities/Institutes
  8. Burkholderia Infections - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Burkholderia Infections - Products under Development by Companies
  13. Burkholderia Infections - Products under Investigation by Universities/Institutes
  14. Burkholderia Infections - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/72pd2r/burkholderia

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Infectious Diseases Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Infectious Diseases Drugs